An Inspire Pharmaceuticals drug for the treatment of cystic fibrosis has been given orphan drug designation by the European Medicines Agency.
The drug, denufosol tetrasodium, was approved for orphan drug status in the United States.
According to the European agency, orphan status products are for diagnosing, preventing of treating life-threatening or very serious conditions that do not affect more than five in 10,000 people in the European Union. Orphan drug status also includes various market incentives such as 10 years of potential market exclusivity.
Inspire Pharmaceuticals: www.inspirepharm.com
